Nastech Breaks Out New RNAi Technologies, Evades Questions About Possible Deal for Dicer-Substrates

At an analyst and institutional investor day, Nastech’s CSO outlined a modification technology the company has developed for siRNA stability and a delivery approach incorporating peptides and lipids. He also mentioned the company’s use of 27-mer siRNAs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.